COVID-19 vaccines: Antibody levels might help speed up approval

Health authorities only approve the use of COVID-19 vaccines that have gone through rigorous clinical trials. Scientists assess whether a vaccine is effective by checking whether participants in a trial develop the infection after having the vaccine. In the present study, researchers find that a person’s antibody response could serve a correlate of effectiveness, instead of whether people develop the infection. Using this proposed measure could speed up the regulatory approval of future vaccines.